Arch Biopartners is set to expand its Phase II clinical trial of LSALT peptide, a drug candidate targeting CS-AKI, to clinical sites in the US.

The post Arch Biopartners plans US expansion of LSALT peptide trial appeared first on Clinical Trials Arena.